TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Functional Improvement in Patients With Parkinson's Disease After Training in Real or Virtual Environment
Brief Summary: The objective of this work was to compare the effects of two balance training programs, one Nintendo Wii Fit-based and the other traditionally-based without the use of a gaming system, on the balance, functionality and cognition of patients with Parkinson´s disease. It was a prospective, single blinded, randomized clinical trial performed at Brazil Parkinson Association and Center of Research of the courses of Speech Therapy, Physical Therapy and Occupational Therapy of São Paulo University. 32 patients with Parkinson´s disease on stages 1 and 2,5 of Hoehn e Yahr participated of this work. Patients were randomized in control and experimental group, 16 each one.

The study was finished at december 2011.


Options:
A: Arm Label: Virtual Reality Training; Type: EXPERIMENTAL; Interventions: Device: Balance Training with Nintendo Wii Fit | Arm Label: Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical Therapy | Intervention Type: DEVICE; Name: Balance Training with Nintendo Wii Fit; Assigned to Arm(s): Virtual Reality Training | Intervention Type: OTHER; Name: Physical Therapy; Assigned to Arm(s): Physical Therapy
B: Arm Label: TT+VR; Type: EXPERIMENTAL; Interventions: Other: TT+VR | Arm Label: TT alone; Type: ACTIVE_COMPARATOR; Interventions: Other: TT alone | Intervention Type: OTHER; Name: TT+VR; Assigned to Arm(s): TT+VR | Intervention Type: OTHER; Name: TT alone; Assigned to Arm(s): TT alone
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Multidisciplinary Care | Arm Label: II; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Multidisciplinary Care; Assigned to Arm(s): I | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): II
D: Arm Label: Virtual reality based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Virtual reality based intervention | Arm Label: Conventional intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional intervention | Intervention Type: BEHAVIORAL; Name: Virtual reality based intervention; Assigned to Arm(s): Virtual reality based intervention | Intervention Type: BEHAVIORAL; Name: Conventional intervention; Assigned to Arm(s): Conventional intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extending the Time for Thrombolysis in Emergency Neurological Deficits
Brief Summary: The primary hypothesis being tested in this trial is that ischaemic stroke patients selected with significant penumbral mismatch (according to imaging criteria) at 4.5 (or 3 hours depending on local guidelines) - 9 hours post onset of stroke or after 'wake up stroke' (WUS) will have improved clinical outcomes when given intravenous tissue plasminogen activator (tPA) compared to placebo.


Options:
A: Arm Label: Desmoteplase, low dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Desmoteplase, high dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, low dose | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: intravenous tissue plasminogen activator; Type: EXPERIMENTAL; Interventions: Drug: Tissue Plasminogen Activator (Alteplase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tissue Plasminogen Activator (Alteplase); Assigned to Arm(s): intravenous tissue plasminogen activator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: IV tPA; Type: EXPERIMENTAL; Interventions: Drug: Tissue Plasminogen Activator (Alteplase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tissue Plasminogen Activator (Alteplase); Assigned to Arm(s): IV tPA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extending the Time for Thrombolysis in Emergency Neurological Deficits
Brief Summary: The primary hypothesis being tested in this trial is that ischaemic stroke patients selected with significant penumbral mismatch (according to imaging criteria) at 4.5 (or 3 hours depending on local guidelines) - 9 hours post onset of stroke or after 'wake up stroke' (WUS) will have improved clinical outcomes when given intravenous tissue plasminogen activator (tPA) compared to placebo.


Options:
A: Arm Label: Thrombectomy; Type: ACTIVE_COMPARATOR; Interventions: Device: Thrombectomy | Arm Label: Best medical care; Type: OTHER; Interventions: Other: Best medical care | Intervention Type: DEVICE; Name: Thrombectomy; Assigned to Arm(s): Thrombectomy | Intervention Type: OTHER; Name: Best medical care; Assigned to Arm(s): Best medical care
B: Arm Label: Group with endovascular treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Rescue endovascular therapy | Arm Label: Group without endovascular treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: No endovascular therapy | Intervention Type: PROCEDURE; Name: Rescue endovascular therapy; Assigned to Arm(s): Group with endovascular treatment | Intervention Type: PROCEDURE; Name: No endovascular therapy; Assigned to Arm(s): Group without endovascular treatment
C: Arm Label: intravenous tissue plasminogen activator; Type: EXPERIMENTAL; Interventions: Drug: Tissue Plasminogen Activator (Alteplase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tissue Plasminogen Activator (Alteplase); Assigned to Arm(s): intravenous tissue plasminogen activator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Alteplase; Type: EXPERIMENTAL; Interventions: Drug: Tissue-type plasminogen activator (alteplase) | Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard care | Intervention Type: DRUG; Name: Tissue-type plasminogen activator (alteplase); Assigned to Arm(s): Alteplase | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of End Stage Kidney Disease by Darbepoetin Alfa In CKD Patients With Non-diabetic Kidney Disease
Brief Summary: The purpose of this study is to ask whether treating non-diabetic chronic kidney disease (CKD) patients with GFR 8-20mL/min/1.73m2 by darbepoetin Alfa targeting Hb between 11.0 and 13.0g/dL preserves renal function better than targeting Hb between 9.0 and11.0g/dL. The investigators also ask whether the higher Hb targeting 11 to 13g/dL will not cause higher adverse events regarding cardiovascular diseases compared with lower Hb targeting 9 to 11g/dL.


Options:
A: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Epoetin; Assigned to Arm(s): N/A
C: Arm Label: High Hb group; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Low Hb group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): High Hb group, Low Hb group
D: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Group Balance Training for People With Multiple Sclerosis
Brief Summary: People with multiple sclerosis (MS) often have affected balance capacity and an increased risk for falls. A risk factor for falls are activities requiring dual attention. Another factor leading to reduced balance capacity is trunk stability, and decreased trunk stability has been seen in people with MS compared to healthy controls. Earlier studies using core stability exercises have shown positive effects on balance, compared to no training. In Sweden, physical therapy for people with MS has often included group training. However, evidence for this intervention is scarce. The aim of this study is therefore to investigate balance training in group. The balance training includes core stability exercises and dual attention activities. A multi-centre study is planned with a waiting-list design. Participants are randomised to either exercise group with early start or with late start. The group balance training includes training 60 minutes 2 times per week for 7 weeks.


Options:
A: Arm Label: Home-based Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based exercise | Arm Label: Education; Type: EXPERIMENTAL; Interventions: Behavioral: Education | Arm Label: Exercise plus education; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise plus Education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home-based exercise; Assigned to Arm(s): Home-based Exercise | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education | Intervention Type: BEHAVIORAL; Name: Exercise plus Education; Assigned to Arm(s): Exercise plus education
B: Arm Label: Group balance training early start; Type: EXPERIMENTAL; Interventions: Other: Group balance training | Arm Label: Group balance training late start; Type: EXPERIMENTAL; Interventions: Other: Group balance training | Intervention Type: OTHER; Name: Group balance training; Assigned to Arm(s): Group balance training early start, Group balance training late start
C: Arm Label: Sensory-motor Integration Training; Type: EXPERIMENTAL; Interventions: Procedure: Sensory-motor Integration Training | Arm Label: Conventional neurorehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional neurorehabilitation treatment | Intervention Type: PROCEDURE; Name: Sensory-motor Integration Training; Assigned to Arm(s): Sensory-motor Integration Training | Intervention Type: PROCEDURE; Name: Conventional neurorehabilitation treatment; Assigned to Arm(s): Conventional neurorehabilitation
D: Arm Label: Free From Falls; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Free From Falls Online | Arm Label: Waitlist; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Waitlist Control | Intervention Type: BEHAVIORAL; Name: Free From Falls Online; Assigned to Arm(s): Free From Falls | Intervention Type: BEHAVIORAL; Name: Waitlist Control; Assigned to Arm(s): Waitlist

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus
Brief Summary: The purpose of this study is to assess the efficacy and safety of vildagliptin 50mg bid add-on therapy to improve overall glycemic control in patients with type 2 diabetes mellitus inadequately controlled on insulin with or without metformin treatment.


Options:
A: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
B: Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Insulin BIAsp30 (Novolog 70/30), Drug: Placebo-Repaglinide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin BIAsp30 (Novolog 70/30), Drug: Repaglinide, Drug: Placebo-Metformin | Arm Label: 1; Type: OTHER; Interventions: Drug: Metformin, Drug: Repaglinide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Insulin BIAsp30 (Novolog 70/30); Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Repaglinide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo-Metformin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo-Repaglinide; Assigned to Arm(s): 3
C: Arm Label: Pramlintide; Type: ACTIVE_COMPARATOR; Interventions: Drug: pramlintide acetate | Intervention Type: DRUG; Name: pramlintide acetate; Assigned to Arm(s): Pramlintide
D: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Dosing Regimens of MEMP1972A in Adults With Allergic Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids and a Second Controller (COSTA)
Brief Summary: This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of 3 dosing regimens of MEMP1972A in patients with allergic asthma who remain inadequately controlled on chronic therapy with high dose inhaled corticosteroids and a second controller medication.Patients will be randomized to 4 Arms to receive subcutaneous repeating dose of either MEMP1972A 150 mg, 300 mg, or 450 mg, or placebo. Patients will continue their usual asthma medication throughout the study. Anticipated time on study treatment is 36 weeks, with a 48-week follow-up.


Options:
A: Arm Label: Mepolizumab; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab 300 mg, Drug: Active OCS capsules (5 mg prednisolone or prednisone), Drug: Placebo matching OCS capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matching mepolizumab, Drug: Active OCS capsules (5 mg prednisolone or prednisone), Drug: Placebo matching OCS capsules | Intervention Type: DRUG; Name: Mepolizumab 300 mg; Assigned to Arm(s): Mepolizumab | Intervention Type: DRUG; Name: Placebo matching mepolizumab; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Active OCS capsules (5 mg prednisolone or prednisone); Assigned to Arm(s): Mepolizumab, Placebo | Intervention Type: DRUG; Name: Placebo matching OCS capsules; Assigned to Arm(s): Mepolizumab, Placebo
B: Arm Label: Benralizumab (Medi-563); Type: EXPERIMENTAL; Interventions: Drug: Benralizumab (Medi-563) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Benralizumab (Medi-563); Assigned to Arm(s): Benralizumab (Medi-563) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Benralizumab; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab
D: Arm Label: MEMP1972A 150 mg; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: MEMP1972A 300 mg; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: MEMP1972A 450 mg; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): MEMP1972A 300 mg | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): MEMP1972A 450 mg | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): MEMP1972A 150 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
Brief Summary: This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated with AGS-003 in combination with standard treatment versus subjects treated with standard treatment alone.


Options:
A: Arm Label: SUNITINIB MALATE.; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib malate | Intervention Type: DRUG; Name: Sunitinib malate; Assigned to Arm(s): SUNITINIB MALATE.
B: Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Behavioral: Quality of Life Assessment | Arm Label: Temsirolimus; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus, Behavioral: Quality of Life Assessment, Drug: Benadryl | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): Temsirolimus | Intervention Type: BEHAVIORAL; Name: Quality of Life Assessment; Assigned to Arm(s): Pazopanib, Temsirolimus | Intervention Type: DRUG; Name: Benadryl; Assigned to Arm(s): Temsirolimus
C: Arm Label: Interleukin-2, interferon, bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: Interleukin-2 and interferon-alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interleukin-2, Drug: Interferon Alfa-2b | Intervention Type: DRUG; Name: Interleukin-2; Assigned to Arm(s): Interleukin-2 and interferon-alfa | Intervention Type: DRUG; Name: Interferon Alfa-2b; Assigned to Arm(s): Interleukin-2 and interferon-alfa | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Interleukin-2, interferon, bevacizumab
D: Arm Label: AGS-003 + Standard Treatment; Type: EXPERIMENTAL; Interventions: Biological: AGS-003 | Arm Label: Standard Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Treatment | Intervention Type: DRUG; Name: Standard Treatment; Assigned to Arm(s): Standard Treatment | Intervention Type: BIOLOGICAL; Name: AGS-003; Assigned to Arm(s): AGS-003 + Standard Treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International GBS Outcome Study (IGOS): a Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS).
Brief Summary: International GBS Outcome Study (IGOS) is a study conducted by the members of the Inflammatory Neuropathy Consortium (INC) and Peripheral Nerve Society (PNS) on disease course and outcome in Guillain-Barré syndrome (GBS).

The IGOS aims to identify clinical and biological determinants and predictors of disease course and outcome in individual patients with Guillain-Barré syndrome, as early as possible after onset of disease.


Options:
A: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
B: Arm Label: GBS; Type: N/A; Interventions: N/A | Arm Label: NC; Type: N/A; Interventions: N/A | Arm Label: IC; Type: N/A; Interventions: N/A | Arm Label: OND; Type: N/A; Interventions: N/A
C: Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eculizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): eculizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Home-Based Symptom Management Via Reflexology for Breast Cancer Patients
Brief Summary: The purpose of this project is to test foot reflexology delivered by a friend or family member in the home for women with breast cancer. The primary aims of the proposed study in a sample of women with breast cancer receiving chemotherapy and/or hormonal therapy are to determine the effects of 4 family- or friend-delivered weekly reflexology sessions compared to an attention control group.


Options:
A: Arm Label: Stepped Care; Type: EXPERIMENTAL; Interventions: Other: Stepped Care | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Stepped Care; Assigned to Arm(s): Stepped Care
B: Arm Label: Interdisciplinary rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Interdisciplinary rehabilitation | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Interdisciplinary rehabilitation; Assigned to Arm(s): Interdisciplinary rehabilitation
C: Arm Label: Connected device; Type: EXPERIMENTAL; Interventions: Device: Connected device | Arm Label: Therapeutic education; Type: EXPERIMENTAL; Interventions: Behavioral: Therapeutic education | Arm Label: Combined; Type: EXPERIMENTAL; Interventions: Device: Connected device, Behavioral: Therapeutic education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Connected device; Assigned to Arm(s): Combined, Connected device | Intervention Type: BEHAVIORAL; Name: Therapeutic education; Assigned to Arm(s): Combined, Therapeutic education
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Reflexology | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Reflexology; Assigned to Arm(s): Intervention

Answer: D